SP-MHCI-0410-3

HER2 (erbB-2) 435-443, ILHNGAYSL

US$507.00

In stock

Description

About HER2 (erbB-2) 435-443, ILHNGAYSL

The Human Receptor tyrosine-protein kinase erbB-2 Peptide (IEDB: 27094) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Receptor tyrosine-protein kinase erbB-2 Peptide, H-ILHNGAYSL-OH (Uniprot: P04626 aa: 435-443) from JPT is produced under strict quality control and quality management.

HER2 (erbB-2) 435-443, ILHNGAYSL - Specifications

  • Peptide sequence: H-ILHNGAYSL-OH
  • Amount: 10 mg (10 x 1 mg)
  • Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
  • Counterion: TFA
  • Delivery Format: Freeze-dried in glass vial
  • Application(s): T-cell Immunity
  • Condition(s)/Topic(s): Breast cancer
  • Standard Delivery Time: approx. 3 weeks

JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Peptide Synthesis Services!

Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!

References

References for HER2 (erbB-2) 435-443, ILHNGAYSL

References:
Read References with JPT’s Antigen Peptides
HER2 (erbB-2) 435-443, ILHNGAYSL has been described in:
Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination., J Exp Med, 2007 (PMID: 17709425)
Chemotherapy and radiation therapy elicits tumor specific T cell responses in a breast cancer patient., BMC Cancer, 2016 (PMID: 27484900)
Variations in BK Polyomavirus Immunodominant Large Tumor Antigen-Specific 9mer CD8 T-Cell Epitopes Predict Altered HLA-Presentation and Immune Failure., Viruses, 2020 (PMID: 33371492)

Documentation

Documentation for HER2 (erbB-2) 435-443, ILHNGAYSL

Properties

Properties of HER2 (erbB-2) 435-443, ILHNGAYSL

Properties Values
Application: T-cell immunity
Category: Antigen Peptides
Condition / Topic: Breast cancer
Layout: Freeze-dried in glass vial
Organism: Human
Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
Quantification: No, Yes

Further Information to HER2 (erbB-2) 435-443, ILHNGAYSL

Information Values
Sequence: H-ILHNGAYSL-OH
Specifications: 9mer peptide as TFA salt
Loading...

Check our list of products, click and go.

Get a quote